Sebastian Gensior

Opus Genetics is a Research Triangle Park, North Carolina-based clinical-stage biopharmaceutical company developing gene therapies for inherited retinal diseases (IRDs). The company trades on the Nasdaq under the ticker IRD and, as of April 14, 2026, carries a market capitalisation of approximately $396 million at a share price

Fund Snapshot Firm Jeito Capital Fund I Jeito I, €534M ($630M), final close September 2021 Fund II Jeito II, >€1B ($1.2B), final close March 31, 2026 Total AUM €1.6B (~$1.9B) Target Portfolio Fund I: 12--15 companies (actual: ~22); Fund II: 15--20 companies Max Single

Understanding the instrument that sits behind every major royalty fund's capital structure and every commercial-stage biotech's liquidity toolkit — how revolvers work, why they matter, and how they interact with royalty financing transactions.

When two pharmaceutical companies or a biotech and a royalty fund negotiate a royalty agreement, the headline debate is almost always about the rate. A licensor argues for 8%. The licensee counters with 5%. They settle at 6.5%, and everyone calls it a done deal. That conversation is the

The conversation about emerging markets in pharmaceutical royalties runs a predictable circuit. China dominates the headlines, Korea is gaining ground, Japan is attracting renewed institutional attention following the analysis in our recent piece on the Japanese market, and Europe — from Basel to Berlin — has been reliably generating mid-market transactions

April 5–10, 2026 saw $9.2 billion in confirmed capital deployed across biopharma, spanning 6 M&A transactions, 6 licensing deals, 3 structured debt/royalty facilities, 14 equity raises, 2 government contracts, and 1 fund close — plus 7 clinical readouts and 5 regulatory actions. Oncology dominated at $3.

The term "Royalty Interest Agent" does not appear as a standardised designation in pharmaceutical royalty financing documentation. Instead, the role is expressed through a set of functionally equivalent but terminologically inconsistent defined terms that vary by transaction, by investor, and by deal counsel. Understanding what this role entails—

Coefficient Bio was a New York-based stealth AI-biotech startup founded in September 2025. On April 3, 2026, Anthropic — the San Francisco-based AI safety company behind the Claude family of models — acquired Coefficient Bio in an all-stock deal valued at just over $400 million. The company had

Overview and Investment Focus Catalio Capital Management is not a traditional venture capital firm — it is a scientist-entrepreneur network turned multi-strategy investment platform. Founded in 2020 by George Petrocheilos and Dr. R. Jacob Vogelstein, and spun out of Camden Partners Holdings, the New York-based firm has built

Pharmaceutical licensing agreements are complex instruments designed to allocate risk between parties with fundamentally different positions. The licensor—often a biotech startup or university—has developed valuable intellectual property but may lack commercial capabilities. The licensee—typically a larger pharmaceutical company—has the infrastructure to commercialize but faces uncertainty about